Synagis (Palivizumab Vials) 100mg

Synagis (Palivizumab) 100mg vials are used to help prevent serious lung infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children. This monoclonal antibody therapy is administered via injection. Store between 2-8°C to maintain potency.

Strength

100mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Astrazeneca

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Synagis (Palivizumab) is a prescription medication used to reduce the risk of severe RSV infections in certain high-risk infants and young children. It is commonly prescribed for premature babies, those with chronic lung disease, or congenital heart disease. The therapy works by providing antibodies to help fight RSV before infection occurs.

Side Effects

Synagis helps the immune system recognize and respond to RSV, potentially reducing the severity of symptoms if an infection occurs. Most patients tolerate the medication well, with reactions typically limited to mild injection-site discomfort. Some may experience temporary fatigue or mild fever after administration.

Precautions & Warnings

Synagis should only be handled and administered by a healthcare professional. Keep vials refrigerated between 2-8°C and protect from light. Do not freeze or shake the vial. Patients with a history of severe allergic reactions to immunoglobulins should discuss risks with their provider before use.

Avoid Interactions

Limited data exists on drug interactions with Synagis, but caution is advised when combining with other immune-modulating therapies. No specific interactions with common medications like antibiotics or pain relievers have been reported. Always inform your healthcare provider about all medications being taken.

Frequently Asked Questions

Synagis is used to help prevent serious lung infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.

Synagis is given as an injection, typically once a month during RSV season, by a healthcare professional.

Synagis is approved for use in infants and young children, not typically prescribed for adults.

Common effects may include mild fever, fatigue, or discomfort at the injection site.

Synagis vials should be kept refrigerated between 2-8°C and protected from light.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.